DTX2P1 as a Potential Drug Target for Cancer (G107161144)

Target Name: DTX2P1

NCBI ID: G107161144

DTX2P1

Other Name(s): DTX2 pseudogene 1

DTX2P1 as a Potential Drug Target for Cancer

DTX2P1, also known as DTX2 pseudogene 1, is a gene that encodes a protein located in the tumor suppressor gene 1 (TSG1) gene family. TSG1 genes are involved in cell growth, apoptosis, and angiogenesis, and are often mutated in various types of cancer.DTX2P1 has been identified as a potential drug target or biomarker in various types of cancer, including breast, ovarian, and colorectal cancers.

DTX2P1 and Cancer

DTX2P1 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. It has been shown to play a role in the development and progression of these cancers by promoting cell survival and angiogenesis.

In breast cancer, DTX2P1 has been shown to promote the growth and survival of breast epithelial cells, and has been identified as a potential therapeutic target. Studies have shown that inhibiting the activity of DTX2P1 using small molecules or antibodies can lead to a reduction in the growth and survival of breast epithelial cells.

In ovarian cancer, DTX2P1 has been shown to contribute to the development and progression of this disease by promoting the growth and survival of ovarian epithelial cells. It has also been identified as a potential therapeutic target, and studies have shown that inhibiting the activity of DTX2P1 using small molecules or antibodies can lead to a reduction in the growth and survival of ovarian epithelial cells.

In colorectal cancer, DTX2P1 has been shown to contribute to the development and progression of this disease by promoting the growth and survival of colorectal epithelial cells. It has also been identified as a potential therapeutic target, and studies have shown that inhibiting the activity of DTX2P1 using small molecules or antibodies can lead to a reduction in the growth and survival of colorectal epithelial cells.

DTX2P1 as a Potential Drug Target

DTX2P1 has been identified as a potential drug target by several studies. These studies have shown that inhibiting the activity of DTX2P1 using small molecules or antibodies can lead to a reduction in the growth and survival of various types of cancer cells, including breast, ovarian, and colorectal cells.

One of the main advantages of DTX2P1 as a potential drug target is its involvement in cell growth and apoptosis. Cancer cells often have increased cell survival and resistance to apoptosis, and inhibiting the activity of DTX2P1 can lead to a reduction in these properties. This can make DTX2P1 an attractive target for cancer treatments that focus on targeting the maintenance of cellular survival and apoptosis.

Another advantage of DTX2P1 as a potential drug target is its role in angiogenesis. Angiogenesis is the process by which new blood vessels form in the body, and is often associated with cancer growth and progression. Inhibiting the activity of DTX2P1 can lead to a reduction in the formation of new blood vessels, which can make it an attractive target for cancer treatments that focus on targeting angiogenesis.

Several small molecules and antibodies have been shown to inhibit the activity of DTX2P1. These molecules have been shown to reduce the growth and survival of various types of cancer cells, including breast, ovarian, and colorectal cells. Some of the most promising small molecules and antibodies for targeting DTX2P1 include:

Conclusion

DTX2P1 is a gene that encodes a protein located in the tumor suppressor gene 1 (TSG1) gene family. TSG1 genes are involved in cell growth, apoptosis, and angiogenesis, and are often mutated in various types of cancer. DTX2P1 has been identified as a potential drug target or biomarker in various types of cancer, including breast, ovarian, and colorectal cancers. It has been shown to play a role in the development and progression of these cancers by promoting cell survival and angiogenesis. Several small molecules and antibodies have been shown to inhibit the activity of DTX2P1, making it an attractive target for cancer treatments that focus on targeting the maintenance of cellular survival and apoptosis, and the formation of new blood vessels. Further studies are needed to

Protein Name: DTX2 Pseudogene 1

The "DTX2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DTX2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets